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Abstract 
Amyloid deposits of wild-type apolipoprotein A-
I (apoA-I), the main protein component of high-
density lipoprotein, accumulate in 
atherosclerotic plaques where they may 
contribute to coronary artery disease by 
increasing plaque burden and instability.  We 
report here a surprising cooperative effect of 
heparin and the green tea polyphenol, (±)-
epigallocatechin-3-gallate (EGCG), a known 
inhibitor and modulator of amyloid formation, 
on apoA-I fibrils.  Heparin, a proxy for 
glycosaminoglycan (GAG) polysaccharides that 
co-localize ubiquitously with amyloid in vivo, 
accelerates the rate of apoA-I formation from 
monomeric protein and associates with the 
insoluble fibrils.  Mature, insoluble apoA-I 
fibrils bind EGCG (Kd = 30 ± 3 PM; Bmax = 40 ± 
3 PM) but EGCG does not alter the kinetics of 
apoA-I amyloid assembly from monomer in the 
presence or absence of heparin.  EGCG 
selectively increases the mobility of specific 
backbone and side chain sites of apoA-I fibrils 
formed in the absence of heparin, but the fibrils 
largely retain their original morphology and 
remain insoluble. By contrast, fibrils formed in 
the presence of heparin are mobilized 
extensively by the addition of equimolar EGCG 
and the fibrils are remodelled into soluble 20 
nm-diameter oligomers with a largely D-helical 
structure that are non-toxic to human umbilical 
artery endothelial cells. These results argue for a 
protective effect of EGCG on apoA-I amyloid 
associated with atherosclerosis and suggest that 
EGCG-induced remodeling of amyloid may be 
tightly regulated by GAGs and other co-factors 
of amyloid in vivo, depending on the 
bioavailability of EGCG. 
 
 Introduction 
Amyloidosis is a group of disorders 
characterized pathologically by the extracellular 
accumulation of insoluble protein fibrils with a 
cross-ȕ structural motif.  Systemic amyloidosis 
affects several organs and tissues, whereas 
localized amyloid is confined to a single organ. 
In each case the clinical manifestations depend 
on the precursor protein (1). Localized amyloid 
GHSRVLWVRIWKH$ȕ peptide in $O]KHLPHU¶s brains 
have been characterized extensively, although 
the relationship EHWZHHQ PLVIROGHG $ȕ and 
disease remains unresolved. The pathological 
consequences of systemic amyloidosis are less 
ambiguous and often involve irreparable damage 
to major organs at the end-stage of disease.  
Systemic amyloid derived from apolipoprotein 
A-I (apoA-I), the major protein component of 
the high density lipoprotein (HDL) complex 
which transports cholesterol to the liver, was 
LGHQWLILHGLQWKH¶V as a hereditary condition 
related to several mutant forms of the protein 
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which are susceptible to protease digestion, 
misfolding and aggregation (2,3). More recent 
evidence has shown that fibrils of wild-type 
apoA-I also accumulate spontaneously in the 
plaques of atherosclerosis and may contribute to 
the condition (4-7).  Lipid-deprived apoA-I can 
undergo an alternative folding pathway in which 
the protein self-assembles into amyloid (8,9), 
resulting in loss of its atheroprotective properties 
and the accumulation of potentially damaging 
amyloid plaques in vital organs and vasculature. 
The high incidence of fibrillar apoA-I associated 
with atherosclerotic lesions suggests that 
amyloid deposition may decrease plaque 
stability and contribute to the progression of 
atherosclerosis (6,7,10,11). 
Native, functional apoA-I has a predominantly 
D-helical structure, but the fibrillar aggregates 
exhibit a combination ofD-KHOLFDO DQG ȕ-sheet 
conformations according to circular dichroism 
and solid-state NMR spectroscopy (12).  ApoA-I 
aggregation in vitro is promoted in an acidic 
environment (11) and by the myeloperoxidase-
catalysed oxidation of methionine residues (13), 
conditions that are associated with inflammatory 
diseases such as atherosclerosis. It has been 
proposed that the local extracellular regions 
surrounding atherosclerotic lesions are acidic, 
and the release of lactic acid by macrophages 
can acidify the local environment to below pH 4 
(14). In addition, heparin, a member of the 
glycosaminoglycan (GAG) polysaccharides that 
co-localize ubiquitously with amyloid in vivo  
(15,16), accelerates the formation of ordered 
apoA-I fibrils in a concentration-dependent 
manner (11,12).  Generally, heparin is known to 
increase the rate of amyloid fibril formation 
(17,18), stabilize fibrils (19,20) and reduce 
amyloid toxicity (21,22).  The GAG chains of 
proteoglycans in the arterial intima associate 
with apoA-I in the advanced stages of 
atherosclerosis (23) and the accumulation of 
high local apoA-I concentrations may contribute 
to the formation and retention of amyloid 
deposits. The native structure of apoA-I is stable 
at pH 7, but at pH 4-5 in the presence of heparin 
aggregation is virtually instantaneous. 
Polyphenols from green tea, including (±)- 
epigallocatechin-3-gallate (EGCG), are 
flavonoids that are considered to have beneficial 
protective effects on cardiovascular health and 
against atherosclerosis, resulting from their anti-
oxidant and anti-inflammatory properties 
(24,25).  EGCG has also been shown to 
modulate the aggregation kinetics of several 
amyloidogenic proteins, LQFOXGLQJ $ȕ Į-
synuclein and amylin, and directs the assembly 
pathway toward the formation of large, off-
pathway and non-toxic oligomers (26-28).  
EGCG remodels insoluble amyloid fibrils into 
amorphous aggregates with reduced toxicity to 
mammalian cells (29).  Oxidized and unoxidized 
EGCG molecules bind to amyloid fibrils through 
engagement of hydrophobic sites (30) and polar 
contacts (31,32), but autooxidation of EGCG 
appears to invoke covalent cross-linking with the 
fibrils that stabilize the remodelled aggregates 
(33). These properties of EGCG offer potential 
therapeutic benefits, and clinical trials of EGCG 
for the treatment of early-stagH$O]KHLPHU¶VDQG
antibody light chain (AL) amyloidosis have been 
completed or are currently active. Low 
bioavailability and intestinal and hepatic 
metabolism are considered potential difficulties 
of medical utilization of the unmodified natural 
product (34,35). Recently it was shown that 
EGCG disaggregated fibrils of the G26R (Iowa) 
mutant of apoA-I and also inhibited fibril 
growth, as assessed by the amyloid-reactive dye 
thioflavin T (ThT) (36). The effects were also 
replicated on the N-terminal 1-83 peptide 
fragment of both the Iowa mutant and wild-type 
protein. A detailed molecular analysis of EGCG 
with wild-type apoA-I associated with 
atherosclerosis, however, has not been reported. 
Here, we show that EGCG interacts with fibrils 
of wild-type, full-length apoA-I preferentially 
over other green tea components without 
modulating apoA-I fibril growth kinetics.  
Circular dichroism (CD), solid-state NMR 
spectroscopy (ssNMR) and transmission electron 
microscopy (TEM) reveal that EGCG remodels 
apoA-I fibrils into soluble non-toxic oligomers 
when fibrils are formed in the presence of 
heparin, but not when fibrils are formed in the 
absence of heparin.  This surprising synergistic 
effect of EGCG and heparin may offer a means 
of influencing the deposition of apoA-I amyloid 
associated with atherosclerosis and possibly 
other amyloid known to associated with GAGs 
in vivo.  
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Results 
Heparin associates with apoA-I fibrils:  Wild-
type apoA-I is known to undergo ThT-
responsive aggregation in solution at pH 4 that is 
accelerated by the addition of heparin (11,12). 
Transmission electron microscopy (TEM) 
indicates that incubation of apoA-I alone at pH 4 
for 3 days results in the deposition of fibrils 
(Figure 1A, left) and distinct deposits of more 
amorphous material (Figure 1A, right), whereas 
incubation of apoA-I with a 2-fold molar excess 
of heparin (assuming a mean Mr of 14.5 kDa) 
results in only fibrils.  The fibrils in the absence 
of heparin are 7-15 nm in diameter and fibrils in 
the presence of heparin are distributed from 10-
21 nm in diameter, although the mean widths are 
not significantly different (Figure 1C). Heparin 
may therefore either influence the aggregation 
process and/or may co-localize with the fibrils, 
as found for other amyloid-forming proteins (37-
41).  None of the TEM images showed any 
evidence of nanoscale structures other than 
fibrils or amorphous aggregates, even after 
shorter incubation times.     
Evidence for heparin binding to the fibrils was 
obtained using a heparinase I assay (42), in 
which the concentration of heparin remaining in 
solution was determined after incubation with 
monomeric apoA-I and removal of the fibrils 
formed after 3 days by sedimentation. From an 
initial concentration of 1 mg/mL, heparin is 
progressively removed from solution by 
increasing amounts of protein (Figure 1D).  
Furthermore, apoA-I fibrils formed in the 
presence of heparin doped with a heparin-
fluorescein conjugate showed strong 
fluorescence enhancement over the background 
protein fluorescence (Figure 1E), consistent with 
co-localization of the fluorophore and fibrils. 
The results thus show that heparin binds to 
apoA-I during or after its aggregation into 
amyloid and precipitates concomitantly with the 
insoluble fibrils. 
 
Selective binding of green tea polyphenols to 
apoA-I fibrils:  To investigate whether apoA-I 
fibrils bind EGCG and other polyphenols from 
green tea, an aqueous green tea solution was 
prepared by microwave extraction of the dried 
leaves. An HPLC method was developed to 
quantify green tea polyphenol and caffeine 
binding to pre-formed fibrils. Insoluble fibrils 
prepared in the absence of heparin at pH 4 (1 
mg/mL monomeric apoA-I) were suspended in 
an aqueous solution of green tea (1 mL) and 
incubated for 12 h with gentle agitation before 
centrifugation and retention of the supernatant 
for analysis.  Control samples of the tea extract 
solution alone were treated in the same way.  
Reverse-phase HPLC of the control solution 
resolves several major components which were 
identified by mass spectrometry (12) and 
quantified with reference to a standard mixture 
of eight green tea catechins of known 
concentration (Figure 2 and Table 1). 
Comparison of the peaks for the fibril-treated 
and control solutions reveals that specific 
components are removed from solution by 
binding to the fibrils. The major component, 
EGCG (peak 5), reduces to <50 % of its initial 
concentration after sedimentation of the apoA-I 
fibrils (Figure 2B) and epicatechin-3-gallate 
(ECG) (peak 7) also shows appreciable binding.  
The 3-gallate moiety, therefore, appears to 
enhance the affinity of the polyphenols to 
associate with apoA-I fibrils. EGCG and ECG 
are also removed from the green tea extract 
when incubated with fibrils of the 40-amino acid 
amyloid-ȕ peptide $ȕ40) (Figure 2C), 
confirming the affinity of these polyphenols for 
amyloid fibrils derived from different proteins.  
Titration of apoA-I fibrils (36 PM monomer 
equivalent concentration) with a solution of pure 
EGCG yields an apparent dissociation constant 
(Kd) and saturation binding concentration (Bmax) 
of 40 ± 4 PM and 45 ± 5 PM, respectively 
(Figure 2D).  Similar values (Kd = 30 ± 3 PM; 
Bmax = 35 ± 3  PM) were obtained when EGCG 
was added to the monomeric protein and 
incubated for 48 h before removing the insoluble 
protein by centrifugation.  In both cases the 
saturation binding concentration of EGCG is 
approximately equimolar. 
  
EGCG does not alter the aggregation kinetics 
of apoA-I:  We next used ThT fluorescence to 
determine whether EGCG influences the kinetics 
of aggregation of apoA-I under conditions 
previously reported to favor apoA-I assembly 
into amyloid (11,12). At pH 4, incubation of 
apoA-I alone results in a slow enhancement of 
ThT fluorescence (Figure 2E). The addition of 
heparin, however, results in a rapid enhancement 
of ThT fluorescence, followed by a further, more 
gradual increase (Figure 2E) (in the absence of 
protein heparin does not affect ThT fluorescence 
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(data not shown)).  Previous work has shown 
that the rapid fluorescence enhancement induced 
by heparin reflects an increase in insoluble, 
partially fibrillar protein (12). A repeat of the 
measurements in the presence of EGCG (2-fold 
molar excess over the protein) or green tea 
extract (containing an estimated 2-fold molar 
excess of EGCG with respect to the protein 
concentration) showed that EGCG and the leaf 
extract do not affect the aggregation kinetics of 
apoA-I, regardless of whether heparin is present. 
This observation contrasts with the reported 
inhibitory effect of EGCG on a peptide fragment 
of the apoAIowa variant (36) and on the amyloid-
E peptide (29,43).  Equimolar EGCG is 
sufficient to cause a marked reduction in ThT 
fluorescence in the presence of M$ȕ40 (the 40-
residue amyloid-E peptide with an additional N-
terminal methionine) without affecting the lag 
time or elongation rate (Figure 2F), consistent 
with the known ability of EGCG and ThT to 
compete for the same binding site (33).  
 
Enhancement of backbone and sidechain 
dynamics within fibrillar apoA-I: A more 
detailed analysis was next carried out to 
determine whether EGCG modulates the 
structure of the apoA-I fibrils as it does for other 
fibrillar proteins (28,29,33,44). Solid-state NMR 
(SSNMR) has recently revealed interesting 
structural features of apoA-I fibrils in which the 
duplication of some cross-peaks in 2D 13C-13C 
spectra suggest that the fibrils comprise a 
mixture of Į-helical elements and new, amyloid-
OLNH ȕ-sheet elements within the fibril 
architecture (12).  2D 13C-13C magic angle 
spinning (MAS) ssNMR spectra of 13C-labeled 
apoA-I fibrils (Figure 3A), prepared at pH 4 
alone or in the presence of heparin, or at pH 6 
after protein oxidation by hydrogen peroxide, 
exhibit similar features, including the same 
duplication of peaks for specific amino acids, 
including alanine, threonine, leucine and valine. 
The duplicated peaks occur in approximately the 
same intensity ratios for each sample, as shown 
E\WKHVOLFHVWKURXJKWKH&Į-&ȕ cross-peaks for 
alanine (Figure 3B), VXJJHVWLQJWKDWWKHĮ-helical 
DQG ȕ-sheet elements, which give rise to the 
differences in chemical shift observed (12), 
occur within a single, common fibril architecture 
(see Discussion).  
After adding EGCG to apoA-I fibrils formed at 
pH 4 in the absence of heparin, several cross-
peaks disappear from the 13C-13C spectrum, 
specifically the cross-peaks assigned to valine, 
threonine and alanine in Į-helical environments 
and the proline &Ȗ-&į cross-peak (Figure 4A, 
left, red spectrum). The remaining cross-peaks 
occur at the same positions as in the spectrum of 
untreated apoA-I fibrils (Figure 4A, left, black 
spectrum). The changes in the spectrum can be 
interpreted as a selective structural remodelling 
of the fibrils, caused by exposure to EGCG.  The 
same cross-peaks disappear from the spectrum 
of apoA-I fibrils assembled in the presence of 
EGCG (Figure 4A, right), indicating that similar 
fibril remodelling occurs regardless of whether 
EGCG is present at the onset or added at the 
end-point of aggregation.  
An explanation for these observations is that 
EGCG increases protein mobility over selective 
regions within the fibrils: this is because cross-
peaks in the 13C-13C spectrum arise from dipolar 
coupling between 13C nuclei and if the couplings 
are reduced by increased motional fluctuations 
then the cross-peaks can weaken in intensity or 
disappear. Increased mobility was tested using 
1H-13C INEPT ssNMR, which detects signals 
only from dynamic regions of fibrillar proteins 
(45). A 1D INEPT spectrum of EGCG-treated 
fibrils reveals several sharp peaks attributable to 
the mobile regions of the protein (Figure 4B, 
red), but the 1D INEPT spectrum of fibrils in the 
absence of EGCG fails to detect any signals after 
24 h of measurement (Figure 4B, black).  These 
results indicate protein mobility within the 
untreated fibrils is enhanced after exposure to 
EGCG. A 2D extension of the 1H-13C INEPT 
experiment on the EGCG-treated fibrils enables 
some of the peaks to be assigned to specific 
amino acids (Figure 4C). Most of the resonances 
occur in the amino acid side-chain region of the 
spectrum (principally from methyl-bearing or 
polar/charged side chains) and there is much less 
signal intensity in the CĮ+Į region, which 
implies that most of the protein backbone 
remains relatively constrained. The resolved 
13&ȕ chemical shifts of the mobile leucine, 
threonine, asparagine, alanine and serine side 
chains are consistent with these residues 
occupying an Į-helical structure (Figure 4C and 
Table 2).  
We next obtained a 2D 1H-13C INEPT spectrum 
of EGCG-treated apoA-I fibrils formed in the 
presence of heparin (Figure 4D, blue).  
Surprisingly, many more signals are observed 
than are seen in the spectrum of EGCG-treated 
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fibrils formed in the absence of heparin (Figure 
4D, red), particularly in the backbone HD/CD 
region shown in Figure 4D.  This observation is 
consistent with even greater mobilization of the 
fibrils formed when heparin is present, including 
enhanced dynamics of the protein backbone 
residues. Heparin and EGCG therefore appear to 
have an unexpected synergistic effect on 
increasing apoA-I mobility within protein fibrils.   
A simulated INEPT spectrum (CD-HD region 
only) based on all 243 apoA-I residues LQDQĮ-
helical environment (Figure 4E) implies that one 
would expect many more resonances to be 
observed if the protein was fully mobilized to an 
equal extent across the entire sequence.   
 
EGCG remodels heparin-promoted apoA-I 
fibrils into oligomers:  We next examined 
whether the increased mobility of apoA-I 
aggregates could originate from resolubilization 
of the fibrils by EGCG.  CD spectroscopy was 
used to detect any structured soluble protein that 
may be released from the fibrils after binding 
EGCG.  Fresh samples of fibrils formed (at pH 
4) after 3 days were incubated with equimolar 
EGCG for 12 h and the remaining insoluble 
material was removed by centrifugation before 
analysis of the supernatant by CD. For control 
experiments the EGCG solution was replaced 
with McIlvaine buffer alone. Little signal is 
observed in the far UV CD spectra of the control 
samples or in the spectra of EGCG-treated fibrils 
formed in the absence of heparin to which 
EGCG had been added (Figure 5A) and reliable 
analysis of the secondary structure could not be 
performed. Hence the concentration of soluble 
protein is low in these samples and most of the 
protein was removed in the insoluble fraction.  
In marked contrast, when fibrils formed in the 
presence of heparin are treated with EGCG, the 
supernatant produces a strong signal in the far 
UV CD that is characteristic of structured, 
soluble protein with Į-helical content (Figure 
5A, red solid line). Quantitative analysis of the 
spectrum using the CONTINILL fitting 
algorithm (Figure 5B, red lines) indicates that 
the structure of the soluble material is ~75 % Į-
helical. The CD spectrum of the native protein 
(Figure 5B, black lines), which is stable in 
solution at pH  7 (12), indicates a similar helical 
content of 68 %. Hence EGCG results in the 
shedding of molecules with a predominantly D-
helical structure from fibrils formed with 
heparin, but it is not clear whether the mobilized 
protein reverts to its native structural state.  
Dynamic light scattering (DLS) analysis of the 
EGCG-treated apoA-I fibrils revealed species 
with a hydrodynamic radius distribution of 5-25 
nm results from dissociation of fibrils assembled 
with heparin whereas none of the other buffer or 
EGCG-treated samples released soluble species 
of this size (Figure 5D). No species larger than 
25 nm were released from the fibrils. Together, 
the SSNMR, CD and DLS data indicate that 
EGCG remodels insoluble apoA-I fibrils into 
soluble D-helical species much more readily 
when the fibrils have formed in the presence of 
heparin.  
The EGCG-treated fibrils (formed alone or with 
heparin) were next centrifuged and the 
morphologies of the soluble species in the 
supernatant and the insoluble material in the 
pellet were visualised using negative stain TEM.  
For the fibrils formed alone, exposure to EGCG 
does not disrupt the fibrillar morphology within 
the insoluble fraction and the soluble fraction is 
virtually free of visible protein aggregates in the 
5-25 nm range (Figure 6A).  By contrast, fibrils 
formed in the presence of heparin are remodelled 
by EGCG into small, granular structures which 
remain insoluble, whilst a proliferation of 
soluble spherical oligomer-like species, 20-30 
nm in diameter are now also present (Figure 6B).  
No such species of apoA-I were observed at any 
point in the absence of EGCG. Indeed, apoA-I 
assembly into fibrils is instantaneous in the 
presence of heparin at pH 4 and is unlikely to 
proceed via oligomeric intermediates.  The 
combined effect of heparin and EGCG appears 
to extensively remodel the apoA-I aggregates 
into unique D-helical oligomers that are 
otherwise not observed in the aggregation 
pathway. In the absence of heparin the effect of 
EGCG is less pronounced and more selective for 
specific regions of the protein. For comparison, 
we also visXDOLVHGWKHHIIHFWRI(*&*RQ$ȕ40 
fibrils (formed by seeding their growth in the 
absence of heparin). The results showed that 
fibrils are fragmented into smaller, spear-like 
structures after treatment with EGCG, as 
reported previously (29), although the smaller 
oligomeric and amorphous species observed in 
the same work are not observed here (Figure 
6C).  
We next investigated whether the soluble apoA-I 
aggregates released by EGCG are toxic to cells 
at varying molar ratios of EGCG to protein.  A 
cell viability assay using the cellular 
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dehydrogenase-sensitive dye WST-8 was used to 
assess the cytotoxicity of EGCG-treated apoA-I 
fibrils to human umbilical artery endothelial 
cells (Figure 7, A and B).  Insoluble fibrils (7.2 
PM monomer equivalent), formed in the absence 
or presence of 14.4 PM heparin, were treated 
with EGCG up to a 5-fold molar excess (i.e., 36 
PM) of the polyphenol over the protein, and the 
solutions were added to the cells after removal 
of the extant insoluble material.  Cell viability is 
not impaired when apoA-1 fibrils are exposed to 
equimolar or lower concentrations of EGCG and 
this is apparent whether or not ApoA-I fibrils are 
formed alone or with heparin (Figure 7, A and 
B). Fibrils treated with higher concentrations of 
EGCG (2-5 fold excess) do show some 
impairment of cell viability (Figure 7, A and B).  
However, control measurements on cells treated 
with 36 PM EGCG, 14.2 PM heparin or 36 PM 
EGCG and 14.2 PM heparin together, all in the 
absence of apoA-I, indicate that the cytotoxic 
effect at higher EGCG concentrations is a direct 
result of excess polyphenol and is not related to 
the presence of apoA-I (Figure 7C). SSNMR, 
DLS, CD and TEM all agree that apoA-I fibrils 
formed in the presence of heparin release soluble 
oligomers after treatment with equimolar EGCG.  
Here the data indicate clearly that the soluble 
oligomers are not cytotoxic.   
 
EGCG interacts with monomeric apoA-I but 
not with heparin:  Exposure of apoA-I fibrils 
formed in the presence of heparin releases 
heparin into the aqueous phase in an EGCG 
concentration-dependent manner (Figure 7D).  
We therefore investigated whether EGCG 
interacts with heparin as well as with the 
monomeric protein.  A solution-state 
waterLOGSY NMR experiment was used to 
detect EGCG binding to heparin and, separately, 
to monomeric apoA-I.  In the waterLOGSY 
experiments bulk water magnetization is 
transferred to EGCG if it binds to the larger 
protein or polysaccharide molecule, resulting in 
resonances for EGCG that are of opposite sign to 
non-interacting compounds.  We here used the 
internal reference trimethylsilylpropanoate 
(TSP) as the non-binding molecule, comparing 
the sign of the peak at 0 ppm with EGCG 
aromatic resonances. WaterLOGSY spectra of 
EGCG alone and in the presence of heparin or 
apoA-I were compared with the corresponding 
1D 1H spectra (Figure 8).  As expected, peaks 
from TSP and EGCG are narrow and have the 
same sign in the 1D and waterLOGSY spectra in 
the absence of either of the macromolecules 
(Figure 8A). In the presence of apoA-I the peaks 
from EGCG broaden and take the opposite sign 
to the TSP peak in the waterLOGSY spectrum 
(Figure 8B), consistent with EGCG-protein 
binding, whereas the spectra of EGCG in the 
presence of heparin do not indicate an 
interaction between the two molecules (Figure 
8C).  
Finally we investigated whether EGCG interacts 
with apoA-I as the unoxidized polyphenol or in 
the form of oxidized quinones. The reactive 
form of EGCG influences whether the 
interaction with apoA-I is covalent or non-
covalent.  EGCG is able to undergo auto-
oxidation, generating quinones and superoxide, 
which in turn promotes further EGCG oxidation 
(46). The quinones can self-react to form 
polymeric species via intermolecular cross-
linking, and can also react covalently with 
available SH or NH2 groups of proteins (47).  
Under oxygenated conditions in solution at pH 
7.4, EGCG was shown to be fully oxidized after 
a 6 h incubation period (33). Here we assessed 
whether the low pH conditions used in the 
aggregation and re-solubilization studies 
protected against EGCG oxidation.   EGCG 
polyphenol absorbs maximally at ~275 nm, but 
oxidation above pH 7 results in a color change 
and shift in the absorbance maximum to 320 nm 
(48).  Here, at pH 4 the maximum absorbance of 
EGCG alone in solution (72 PM) remained 
unchanged for 3 days with no evidence of 
additional absorbance bands appearing above 
320 nm (data not shown), indicating that the 
polyphenol alone remains stable under these 
conditions.  We next used LCMS to determine 
whether EGCG undergoes oxidation over time in 
the presence of apoA-I. The LCMS 
chromatograms for fresh and aged (up to 3 days) 
solutions of EGCG and apoA-I, with or without 
heparin showed an intense peak at 7.65 min 
(Figure 9A).  The peak area does not decrease 
significantly when measured after incubation of 
EGCG and apoA-I for 1, 2 and 3 days (in fact, a 
slight unexplained increase is observed) and no 
additional peaks consistent with oxidation or 
degradation products can be seen (Figure 9B). 
The [M+H]+ and [M-H]- peaks in the positive 
and negative polarity scans respectively were 
used to obtain extracted ion chromatograms 
(XIC) from which peak integration values were 
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obtained. For both positive and negative 
ionisation modes the base peak observed at 
7.65 min was assigned to a commonly observed 
adduction of unmodified EGCG at 459.0903 m/z 
and 457.08 m/z, respectively (Figure 9C). 
Finally we checked whether fibrils of apoA-I 
could be covalently modified by EGCG, using 
ssNMR and 15N-labelled protein (in the absence 
of heparin). The 15N MAS NMR spectrum of 
apoA-I fibrils alone exhibit clear peaks from the 
lysine and arginine NH2 groups (Figure 9D), 
which remain unchanged when the fibrils were 
incubated with EGCG for 1 day. A decrease in 
the lysine peak intensities and the appearance of 
peaks at higher chemical shifts (>120 ppm for 
Schiff bases) would be expected if the primary 
amines were covalently modified.  We conclude, 
therefore, that EGCG does not oxidize or 
covalently modify apoA-I under the conditions 
applied here.     
 
 
Discussion 
In the above experiments we set out to 
investigate whether EGCG exerts a potentially 
protective effect on apoA-I amyloid that is 
associated with atherosclerosis, as reported for 
several other amyloidogenic proteins associated 
with disease (49,50). Studies on $ȕ40/42 Į-
synuclein, amylin, huntingtin and transthyretin 
have all shown a common ability of EGCG to 
bind to the oligomeric and multimeric forms of 
amyloid, to inhibit fibril assembly and to prevent 
formation of toxic structures (28,29,51-55). In 
WKH FDVH RI ERWK $ȕ40/42 DQG Į-synuclein, 
EGCG prevents fibrillogenesis by binding 
preferentially to unfolded protein, directing 
assembly towards off-pathway non-toxic 
oligomers and thereby preventing formation of 
toxic oligomers and protofibrils (29). When 
added to pre-formed aggregates, EGCG can also 
alter their ȕ-sheet conformation and convert 
aggregates into small, non-toxic amorphous 
aggregates (28,29). Remodelling of amyloid 
from several different proteins may also involve 
auto-oxidation of EGCG, which can result in 
covalent modification of free amine groups, 
although this mechanism is not the major driving 
force for the structural remodelling (33). Here 
we have identified similarities but also reveal a 
remarkable and hitherto unknown synergy 
between the effect of this polyphenol and the 
GAG heparin on the behaviour of an amyloid 
aggregate.  
In order to rationalize our observations it is 
convenient to consider the structural features of 
apoA-I aggregates at the molecular level.  
ApoA-I forms ThT-responsive aggregates under 
oxidative or acidic conditions and the process is 
accelerated by the GAG analogue heparin, which 
co-localizes with the fibrils (Figure 1).  In the 
latter regard, apoA-,EHKDYHVVLPLODUO\WR$ȕĮ-
synuclein and amylin, all of which assemble into 
amyloid more rapidly in the presence of heparin 
(42,56-59). In some cases heparin decorates the 
surface of the fibrils, such as in salmon 
calcitonin fibrils (60) and in the 3Q fibrils of 
$ȕ40 (42,45,59), whilst in other cases heparin 
does not form a stable complex with the 
insoluble fibrils (61).  The apoA-I aggregates 
formed under the conditions employed here are 
predominantly fibrillar (~10 nm diameter) which 
form alongside amorphous material that is 
known to form DURXQGWKHQDWLYHSURWHLQ¶VS,RI
5.2 (62).  SsNMR spectra reveal the co-existence 
of Į-KHOLFDO DQG ȕ-sheet secondary structural 
elements in approximately the same proportions 
in the apoA-I aggregates, regardless of the 
aggregation conditions employed (Figure 4).  
We believe that both structural elements occur 
within a single fibrillar architecture, such that 
each protein molecule within an aggregate 
possesses both ȕ-sheet and Į-helical regions. An 
alternative explanation, that apoA-I assembles 
via two divergent pathways into discrete 
assemblies of H[WHQVLYHO\ ȕ-sheet protein and 
predominantly Į-helical protein, is also possible.   
EGCG is the major polyphenol component of 
green tea known bind to pre-formed aggregates 
of apoA-I.   EGCG has been shown to interact 
with Ile, Phe and Tyr residues, preventing the 
hydrophobic contacts required for conversion to 
a stable ȕ-sheet conformation and enabling 
disaggregation of pre-formed amyloid fibrils 
(63).  $ȕ40 assembles into fibrils via 
conformationally labile states, potentially 
enabling access of EGCG to block hydrophobic 
contacts, but the compact native structure of 
lipid-free apoA-I (64) and its ability to form 
abundance of hydrophobic contacts stabilizing 
the native helical bundle may overcome any 
inhibitory effect that EGCG may exert. 
The most striking outcome of this work is the 
effect of heparin on the ability of EGCG to 
restructure aggregates of apoA-I. In the absence 
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of heparin, EGCG selectively mobilizes alanine, 
valine and threonine sidechain within D-helical 
regions and proline residues are also affected 
(Figure 4).  Proline residues occur throughout 
the apoA-I sequence and punctuate the helical 
regions with hinges, enabling the protein to form 
the annular belt-like structure associated with 
HDL (65). The INEPT ssNMR experiments 
indicate that the amino acid side-chains are 
mobilized to a greater extent than the backbone 
(Figure 4C), which implies that EGCG acts 
largely peripherally, leaving the stable ȕ-sheet 
core of the fibrils intact. When EGCG is added 
to fibrils assembled in the presence of heparin its 
remodelling effect is amplified significantly, 
yielding an abundance of spherical oligomers ~ 
20 nm in diameter that are non-toxic to human 
endothelial cells.  
How do heparin and EGCG cooperate to 
remodel apoA-I fibrils? A direct interaction 
between EGCG and heparin was ruled out by 
waterLOGSY NMR experiments. Heparin was 
also shown to enhance the aggregation kinetics 
of apoA-I (Figure 2D), likely by the high local 
ionic strength micro-environment of heparin 
combined with the directionality and periodicity 
of its anionic groups that may act as a template 
for apoA-I assembly (66).  The SSNMR spectra 
do not support major structural differences in the 
fibrils formed with or without heparin (Figure 
3), but it is possible that subtle structural 
modifications by heparin could open up 
additional binding sites for EGCG. 
Alternatively, the partial mobilization of the 
fibrils by EGCG seen in the absence of heparin 
could be amplified by heparin when bound to the 
fibril surface.    
The lack of cellular toxicity of the soluble 
oligomers promoted by EGCG in the presence of 
heparin, when taken together with their absence 
during the fibril assembly pathway, suggests that 
these are unique species formed specifically by 
the action of EGCG on the fibrils, rather than a 
regeneration of on-pathway, toxic annular 
oligomers that are observed for other 
amyloidogenic peptides and proteins (67). 
Annular species have been observed when 
methionine-oxidized apoA-I undergoes 
aggregation at pH 6 (68), but these are not 
formed reproducibly and are in much smaller 
amounts than the profusion of oligomers 
observed here.  Why the oligomers are not toxic 
is unclear.    EGCG binds to pre-formed 
oligomers of D-synuclein and protects against 
their inherent cytotoxicity by inhibiting 
oligomer-membrane interactions (69). A similar 
mechanism might underlie the observations on 
apoA-I, but cannot easily be tested owing to the 
inability to prepare pre-formed oligomers in the 
absence of EGCG. 
The ability of EGCG to reproduce the observed 
effects in vivo is dependent on the available 
concentration of EGCG in blood and in the 
aortic intima.  EGCG reaches maximum plasma 
concentration 2 h after drinking a cup of green 
tea, but the steady-state concentration may be 
much higher for frequent green tea drinkers (70).  
Studies with human serum albumin (HSA) 
indicate that EGCG binds to two high affinity 
sites (KD = 22 PM) and several additional low-
affinity surface sites (mM KD), suggesting that 
plasma concentrations of HSA (~600 PM) can 
bind up to 98 % of EGCG (71).  This would 
account for the slow metabolism of EGCG, but 
could also restrict its availability for interactions 
with amyloid proteins, including AE, D-
synuclein and apoA-I.  However, as Eaton and 
Williamson point out in their recent work (71), 
the weaker (millimolar) binding implies fast off-
rates and the weakly bound EGCG would 
dissociate at a rate of 100 s-1 or faster (assuming 
the association rate is at the diffusion-limit). 
Hence the exchange of EGCG between HSA and 
tissue is likely to be rapid. With regard to the 
atherosclerotic environment, HSA and its cargo 
can enter the proteoglycan-rich intimal layer of 
the aorta from the luminal and adventitial sides 
(72), and the concentration of HSA in the 
interstitial space is approximately half that in 
plasma (73).  Further detailed experiments, 
beyond the scope of this work, will be required 
to establish whether the local acidic environment 
of atheromatous tissue enhances the release of 
sufficient EGCG from HSA for interaction with 
fibrillar apoA-I.  It is interesting to note, 
however, that EGCG affinity for bovine serum 
albumin decreases in acidic solution (74).       
In summary, we demonstrate here an unusual 
interplay between apoA-I, EGCG and heparin 
that, together, mobilize fibrils and result in the 
shedding of non-toxic oligomers that does not 
occur in the presence of either ligand alone. The 
results add a layer of complexity in considering 
the effects of small molecules on the progress of 
amyloid assembly and amyloid-associated 
cytotoxicity in a cellular context, wherein other 
components such as GAGs may affect the 
outcome of administration of a small molecule. 
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Indeed number of natural GAG variants have 
been identified as co-localizing with amyloid 
plaques, including chondroitin sulfate (75-77), 
dermatan sulfate (78), and keratan sulfate (79), 
all of which, like heparin and HS, contain poly-
sulfated disaccharide units. Whether fibril 
mobilization is a benefit or a threat may also be 
reconsidered, where reduction of fibril load may 
be of greater benefit than the production of small 
amounts of oligomers, which may be degraded, 
further dissociated by binding to molecular 
chaperones in vivo. Whichever the outcome, the 
results presented suggest that it may now be 
appropriate to re-evaluate the wider, potentially 
protective effects of EGCG as an amyloid 
remodelling agent, by considering the 
synergistic effects of GAGs and other ubiquitous 
co-factors of amyloid in vivo.   
 
Methods and Materials 
Protein expression and fibril formation: 
Expression of N-terminally His-tagged apoA-I 
was carried out by following previously 
published methods (80,81). A pNFXex 
expression vector coding for human apoA-I with 
an N-terminal His tag (kindly provided by Dr M. 
Oda, Oakland Research Institute, USA) was 
transformed into E. coli BL21 (DE3) cells 
(Agilent Technologies) and grown at 37°C in LB 
PHGLDFRQWDLQLQJȝJPODPSLFLOOLQ0HOIRUG
Laboratories). The plasmid construct expresses 
apoA-I with a E2D mutation enabling removal 
of the His-tag by cleavage of the acid-labile 
Asp2-Pro3 peptide bond with formic acid, 
leaving the native residues 3-243.The remaining 
expression and purification methods are 
described in ref (12).   
ApoA-I fibrils were formed from up to 36 PM 
apoA-I incubated in McIlvaine Buffer (165 mM 
Na2HPO4, 17.6 mM citrate, pH 4), typically for 3 
d (unless specified otherwise), alone or in the 
presence of a 2-fold molar excess of heparin 
(IdoA(2S)-GlcNS(6S) 14-15 kDa, >70 %, 
,GXURQ  ([SUHVVLRQ RI 0$ȕ40 and fibril 
formation by seeding with the 3-fold 
symmetrical (3Q) morphology was carried out as 
described previously (45).  
 
Isolation of polyphenol compounds from 
green tea: *UHHQ WHD  J 7ZLQLQJ¶V SXUH
was added to 40 mL of water. The solution was 
microwaved at 900 W of power for 2 cycles of 
30 seconds, followed by 4 cycles of 15 seconds 
with a minute between each heating. The 
VROXWLRQZDVILOWHUHG WKURXJKDȝPILOWHUSDSHU
:KDWPDQ DQG ILOWHUHG ZLWK D  ȝP FRUQLQJ
syringe filter. The solution was then freeze-dried 
until further use. 
 
HPLC analysis of green tea compounds: A 
stock solution of the green tea extract was 
prepared by dissolving the lyophilized material 
in water (7.2 mg/ml) for analysis by reverse-
phase high performance liquid chromatography 
(HPLC). The pH of the solution was 7.5. A 
standard mixture of 8 green tea catechins (each 
at 100 Pg/mL) (Sigma, UK) was used as a 
reference set to assist in the assignment of HPLC 
peaks. Separation was performed on a NexeraX2 
UHPLC (Shimadzu) system with a mobile phase 
of 0.1 % orthophosphate in ultrapure water (A) 
or in acetonitrile (B), whilst the static phase 
consisted of a Shim-pack XR-2'6ȝP, 3.0 x 
50 mm) reverse phase column. The green tea 
stock solution was injected after a further 10-
fold dilution in water and the standard catechin 
solution was injected without further treatment. 
The injection volume was 10 PL in both cases. 
The gradient elution, at a flow rate of 1 mL/min 
consisted of 0-3 minutes (5% of B), 3-10 min (5-
20 % B), 10-13 min (20-50 %) and 13-13.1 min 
(50-5 % B) and 13.1-20 min (5 % B). 
Absorbance intensity was measured at 275 nm 
with a band width of 4 nm. 
For determination of green tea polyphenol 
binding to apoA-I D  ȝ/ VXVSHQVLRQ RI
apoA-,ILEULOVȝ0PRQRPHUHTXLYDOHQWZDV
centrifuged for 10 min at 12,000 g. The green tea 
stock solution was diluted 200-fold in water and 
 ȝ/ ZDV DGGHG WR WKH ILEULOODU SHOOHWV
followed by incubation with agitation at 37°C 
for 24 h. The fibrils were pelleted through 
centrifugation and the supernatant removed 
without further treatment for analysis by HPLC 
as described above.  
 
LCMS Analysis of EGCG: ApoA-1 (36 µM) 
plus 72 µM EGCG was acidified at pH 4 in the 
presence and absence of 72 µM heparin and 
fibrils allowed to form over 3 days at 37 °C with 
shaking. At intervals of 0, 1, 2 and 3 days, the 
samples were centrifuged and 50 µl aliquots of 
supernatant taken for further testing by LCMS. 
Mass spectra were acquired using a Shimadzu 
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LCMS-IT-TOF mass spectrometer.  LC 
separations were performed using a Shimadzu 
NexeraX2 UHPLC instrument consisting of a 
DGU-20A5R degassing unit, two LC-30AD 
liquid chromatography pumps, a SIL-30AC 
autosampler, and a CTO-20AC column oven.  
Separation was performed using a Shim-pack 
XR-ODS (3.0 x 50 mm, 2.2 mm) column with 
an oven temperature of 35°C.  The mobile phase 
comprised of water with 0.1 % formic acid (A) 
and acetonitrile with 0.1% formic acid (B).  A 
binary gradient elution of 0.0-3.0 min 5 % B, 
10.0 min 20 % B, 10.1 min 50 % B, 13.0 min 50 
% B, 13.1 min 5% B, 20.0 min 5 % B, at a flow 
rate of 0.5 mL/min.  High resolution mass 
spectrometric (HRMS) data was measure using 
an electrospray ionisation (ESI) probe with a 
CDL and a heat block temperature of 200°C, and 
an N2 nebulising gas flow rate of 1.5 L/min.  
Data acquisition was performed in both positive 
and negative ionisation with polarity switching.  
A positive acquisition range of 100-1000 m/z 
with ion accumulation at 5.0 msec, and a 
negative acquisition range of 200-1000 m/z with 
ion accumulation at 2.0 msec.  Samples were 
held in the autosampler at 5 °C whilst queued for 
analysis.  The LCMS-IT-TOF mass accuracy 
was calibrated with sodium trifluoroacetate 
clusters prior to analysis of the batch of samples.  
LCMS data was analysed using Shimadzu 
LCMSsolution software, peak areas were 
calculated for the predicted m/z value of [M+H]+ 
ion and [M-H]- ions in positive and negative 
ionisation scan modes respectively, using the 
Qualitative Peak Integration function in the 
LCMS Postrun Analysis software. 
 
Binding of heparin to apoA-I fibrils: ,Q YLWUR
ELQGLQJ DVVD\V RI DSR$-, ILEULO-KHSDULQ ELQGLQJ
ZHUH SHUIRUPHG XVLQJ DQ DGDSWDWLRQ RI D
SURFHGXUH GHVFULEHG SUHYLRXVO\  LQ ZKLFK
WKH DPRXQW RI *$* UHPDLQLQJ XQERXQG DW
GLIIHUHQW ILEULO*$* FRQFHQWUDWLRQ UDWLRV was 
determined using Bacteroides heparinase I (New 
England Biolabs (UK) Ltd).  The heparinase 
enzyme cleaves heparin yielding oligosaccharide 
products containing unsaturated uronic acids, 
which can be detected using UV spectroscopy at 
232 nm. Fibrils were prepared by acidification of 
apoA-I in the presence of heparin (Sigma), at the 
following protein/heparin molar ratios: 1:0.5, 1:1 
and 1:2. In addition samples of protein only and 
heparin only were prepared as controls. In all 
cases the heparin concentration was kept at 1 
mg/ml (72 µM). ApoA-I was initially solubilized 
LQS+0F,OYDLQH¶VEXIIHUWRJHWKHUZLWKKHSDULQ
before carrying out a shift to pH 4 with the 
addition of concentrated HCl. Samples were 
incubated at 37 °C for 3 d with shaking to allow 
fibril formation prior to sedimentation of the 
protein. The supernatant was removed and 
returned to pH 7 with 5M NaOH before assay. 
Samples were monitored at 30 °C, with A232 
measurements taken every 10 s until maximal 
absorbance was reached. The amount of heparin 
remaining in solution was then calculated from a 
heparin calibration curve. 
 
Effect of green tea compounds on the 
aggregation of apoA-I: ThT fluorescence 
experiments were carried out as described in ref 
(12). Briefly, apoA-,  ȝ0 ZDV LQFXEDWHG
with ThT alone anGLQWKHSUHVHQFHRIȝ0
heparin. Samples (in triplicate) were incubated 
with no further additives, or with pure green tea 
extract solution (6.6 ng/mL, roughly equivalent 
to a 2-fold molar excess of EGCG) or 14.4 PM 
EGCG. After measuring the fluorescence for 10 
minutes, concentrated HCl was added to reduce 
the sample to pH 4 and induce aggregation. ThT 
fluorescence measurements were taken over 300 
minutes at 1 min intervals. 
 
Binding of EGCG to apoA-I fibrils: ApoA-I 
ȝ0ZDVLQFXEDWHGalone or with increasing 
concentrations of EGCG at pH 4, 37°C for 3 d 
with agitation. After this time, the fibrils of 
apoA-I formed in the absence of EGCG were 
incubated for a further 24 h in the presence of 
EGCG. The insoluble material was removed by 
centrifugation at 13,400 rpm in a bench-top 
centrifuge. The absorbance of the supernatant at 
274 nm (the wavelength of maximum absorption 
of EGCG) was measured and used to determine 
how much EGCG remained in solution by 
comparison with a standard curve of A274 for 
EGCG at a range of concentrations from 0.01 
mM to 1 mM.  
 
Transmission electron microscopy: ApoA-I 
ȝ0LQWKHDEVHQFHDQGSUHVHQFHRIKHSDULQ
 ȝ0 ZDV LQFXEDWHG DW S+ , 37°C with 
agitation for 3 days. Samples were centrifuged 
and the pellets washed several times with 
distilled water to remove buffer salts. Some 
pellets were resuspended in 36 PM EGCG and 
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incubated overnight at 25°C before removal of 
the bulk solution by centrifugation.  Pellets were 
WKHQGLOXWHGWRȝ0EHIRUHȝ/ZDVORDGHG
onto carbon-coated copper grids and incubated 
30s. Excess sample was removed by blotting. 
Grids (Agar Scientific Ltd., Stansted, UK) were 
washed with 2 x 10 µL water. The grid was then 
stained by inverting it onto a 10 µL droplet of 2 
% (w/v) uranyl acetate and blotting, followed by 
addition of another 10 µL uranyl acetate droplet. 
After 30 seconds of staining, the grid was blotted 
and left to dry for 5 minutes at room 
temperature. The sample was then visualised on 
a JEOL JEM-1400 electron microscope at 100 
kV. TEM images were calibrated in ImageJ 
(NIH) using the TEM scale bar on each image. 
Calibrated lines were drawn to measure fibril 
width for a total of 25 instances per image. 
These instances could include up to three 
measurements of the same fibril at different 
positions in the image. A total of five images for 
ApoA alone and five images of ApoA + heparin 
were analyzed, resulting in an average fibril 
width of 10.7 nm ± 0.4 nm for ApoA alone and 
15.4 nm ± 1.3 nm for ApoA + heparin. All 
measurements were then binned into 1 nm 
categories for data presentation. 
 
 
Circular dichroism spectroscopy: ApoA-I (36 
ȝ0DORQHRULQWKHSUHVHQFHRIKHSDULQȝ0 
was incubated at pH 4, 37 °C for 3 d with 
agitation. The samples were centrifuged and the 
pellets washed several times with distilled water 
to remove buffer salts. The aggregated apoA-I 
was resuspended in McIlvaine buffer, or 
McIlvaine buffer containing 36 ȝ0(*&*7KH
samples were then incubated at 37 °C with 
agitation for 24 hours and then centrifuged at 
14,000 rpm to remove the insoluble aggregated 
protein. Spectra of the supernatants were 
acquired on a Chirascan Plus CD spectrometer 
between 180 and 260 nm with a bandwidth of 1 
nm, using a path length of 0.2 mm. Background 
signals (i.e. from buffer, heparin, EGCG or 
EGCG and heparin) were subtracted and the 
spectra were analysed using CDApps software 
(83).  Fitting was performed using the 
CONTINLL algorithm.  
 
Dynamic Light Scattering: ApoA-I (36 ȝ0LQ
WKH DEVHQFH DQG SUHVHQFH RI KHSDULQ  ȝ0
was incubated at pH 4, 37°C with agitation for 3 
days. Insoluble fibrils were centrifuged and 
washed 3 times with distilled water to remove 
buffer salts. The fibrils were resuspended in 
McIlvaine buffer, or McIlvaine buffer with 36 
ȝ0(*&*DQG LQFXEDWHGDW&IRUKRXUV
The insoluble aggregated material was removed 
through centrifugation at 14,000 rpm, and the 
supernatant loaded into low volume plastic 
cuvettes. DLS spectra were acquired on a 
Zetasizer Nano Zs instrument. The size 
distribution (nm) by percentage volume was 
recorded and averaged over 3 scans. 
 
Solid-state NMR: Uniformly 13C-labelled 
apoA-,  PJ DW  ȝ0 ZDV LQFXEDWHG with 
agitation at pH 4, 37°C for 3 d alone or in the 
presence of 72 M heparin or with 72 PM heparin 
and 36 PM EGCG. Following the production of 
insoluble material, aggregates were harvested by 
centrifugation at 12,000 g for 10 minutes.  The 
aggregates were either centrifuged into a 
zirconium 3.2 mm rotor with a Kel-F cap 
(Bruker, U.K). In some samples EGCG (36 PM) 
was added in a volume of 5 mL to the apoA-I 
samples and left for 24 hours before transferring 
the pellet to the NMR rotor. 
Two-dimensional 13C-13C SSNMR spectra were 
recorded at a magnetic field of 16.3 Tesla on a 
Bruker Avance III 700 spectrometer, with a 3.2 
mm HXY probe operating in double resonance 
mode. Spectra were obtained with magic angle 
spinning at 14 kHz. Hartmann-Hahn cross-
polarization was achieved with a 2 ms contact 
time, and 100 kHz proton decoupling with 
SPINAL-64 applied during signal acquisition. 
During the mixing time of 20 ms, the 1H 
nutation frequency was lowered to 14 kHz, to 
achieve dipolar-assisted rotational resonance 
(DARR) mixing.  A total of 256 t1 increments 
were recorded using the States-TPPI method for 
phase sensitivity, with 256 transients per 
increment.  One and two-dimensional refocused 
INEPT SSNMR spectra (84) and proton-
decoupled 15N cross-polarisation magic-angle 
spinning (CP-MAS) spectra were recorded at a 
magnetic field of 9.3 Tesla on a Bruker Avance 
III 400 spectrometer. Spectra were obtained with 
magic-angle spinning at 8 kHz.  For CP-MAS, a 
contact time of 2 ms and proton spin-lock 
frequency of 63 kHz were applied, with proton 
decoupling at 83 kHz.   
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Solution-state NMR: Proton spectra were 
recorded at a magnetic field of 9.3 Tesla.  
Spectra were obtained for EGCG (360 PM) in 10 
mM phosphate buffer, pH 7, alone or in the 
presence of heparin (ȝ0) or apoA-I (ȝ0).  
1D gradient NOESY experiments were acquired 
with relaxation delays of 2 s, a mixing time of 10 
ms, a presaturation power of 25 Hz and 128 
scans. Gradient strengths were the default for 
this sequence: GPZ1 50%, GPZ2 -10%. Spectral 
width was 8012.82 Hz, the offset on-resonance 
with the water peak, and 64k points (acquisition 
time 4.1 s). Spectra were zero-filled once and 
processed with a 0.3 Hz exponential line-
broadening.  WaterLOGSY spectra were 
acquired with relaxation delays of 1 s, a mixing 
time of 1.7 s, 2 dummy scans and 128 scans. No 
spin-lock was applied in order to observe the 
receptor signals. The selective inversion pulse 
for the NOESY block was a 7.5 ms Gaussian 
pulse, while that in the excitation sculpting block 
was a 2 ms sinc pulse (again, the prosol 
defaults). The spectral width was 6393.862 Hz, 
the offset on-resonance with the water peak, and 
16 k points (acquisition time 1.28 s). Spectra 
were zero-filled once and processed with a 1 Hz 
exponential line-broadening. 
 
Cell Viability: Human umbilical artery 
endothelial cells (HUAEC) (Sigma) were plated 
on 96 well plates at a cell density of ~ 5000 cells 
per well and grown over night at 37 °C to allow 
the cells to adhere. ApoA-1 aggregates (72 µM) 
were formed over 3 days at pH 4 in the presence 
or absence of 144 µM heparin. Fibrils were 
SHOOHWHG DQGZDVKHG[ LQS+0F,OYDLQH¶V WR
remove any unaggregated material, before re-
suspending at the same concentrations. Samples 
were divided in to equal volume aliquots and 
EGCG added at a range of concentrations to give 
molar ratios of 0, 0.1, 0.2, 0.5, 1, 2 and 5:1 
EGCG: apoA-1, and left for a further 24 h, 
before the addition of 10 µl samples to the cells 
(100 µl assay volume). Following incubation at 
37 °C for 48 h, 10 µl of the Cell Counting Kit 
(CCK-8) (Sigma), solution was added and 
incubated for a further 3 h prior to absorbance 
PHDVXUHPHQWDWQP 
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Footnotes 
The abbreviations used are: $ȕDP\ORLG-EHWD$ȕ, amyloid beta (1-40); AL, antibody light chain; 
ApoA-I, aplipoprotein A-I; CD, circular dichroism; DARR, dipole-assisted rotational resonance; 
DLS, dynamic light scattering; ECG, epicathin-3-gallate; EGCG, epigallocathin-3-gallate; GAG, 
glycosaminoglycan; HDL, high density lipoprotein; HPLC, high-performance liquid chromatography; 
HUAEC, human umbilical artery endothelial cells; INEPT, insensitive nuclei enhanced by 
polarization transfer; MAS, magic angle spinning; NMR, nuclear magnetic resonance; ssNME, solid 
state nuclear magnetic resonance; TEM, transmission electron microscopy; ThT, Thioflavin-T; TSP, 
trimethylsilylpropanoate.   
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Table 1. ApoA-I fibril binding of microwave-extracted green tea catechins as quantified from the 
HPLC peak intensities. Fibrils formed from 36 PM apoA-I were centrifuged and resuspended in 200 
ml green tea extract solution before further centrifugation and HPLC analysis of the supernatant.   
 
 Concentration 
Compound ,QLWLDOȝJPOa %RXQGȝJPOb Bound (%) 
1. Gallocatechin 337.1 7.3 2.2 
2. Catechin 506.4 46.0 9.1 
3. Caffeine 302.9 62.6 20.7 
4. Epicatechin 154.9 0 0 
5. Epigallocatechin-3-gallate 958.7 533.2 55.6 
6. Gallocatechin-3-gallatec 35.2 24.8 70.6 
7. Epicatechin-3-gallate 200.3 98.0 48.9 
8. Catechin-3- gallatec 52.7 9.7 18.5 
aInitial concentrations before addition of fibrils were estimated from a peak-by-peak comparison of 
the HPLC chromatograms of the microwave extracted solution and  the standard green tea solution. 
bBound concentrations are given as the initial concentrations minus the supernatant concentrations 
after addition and sedimentation of the fibrils.  
cApproximate values only, as concentrations too low to measure accurately. 
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Table 2. Measured chemical shifts from the 1H-13C INEPT SSNMR spectrum of apoA-I fibrils treated 
with EGCG and mean predicted chemical shifts for the given amino acids in D-helical and E-sheet 
environments. Chemical shifts are reported relative to tetramethylsilane. 
 
Amino acid 13CE chemical shift (ppm) 
 Measured Predicted 
(D-helix/E-sheet) 
Ala 18.23 18.30/21.72 
Asp 39.72 40.50/42.78 
Leu 41.21 41.40/44.02 
Met 31.72 31.70/34.34 
Ser 62.69 62.81/65.39 
Thr 68.68 68.64/70.82 
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Figure 1. ApoA-I fibril formation in the absence or presence of heparin. (A) Negative stain TEM 
images of apoA-I aggregates formed at pH 4 in the absence of heparin.  (B) TEM images of apoA-I 
fibrils formed in the presence of 14-15 kDa heparin (2-fold molar excess). (C) Distribution and means 
of fibril widths measured from TEM images of apoA-I +/- heparin.  (D) Determination of heparin 
association with apoA-I fibrils. Left: time course of uronic acid generation resulting from heparin 
cleavage by heparinase I. Right: Calculation of heparin remaining in solution following sedimentation 
with the protein at different molar ratios. 'A232 was measured as the endpoint A232 value minus the 
initial A232.  All initial solutions contained 1 mg/ml heparin (~72 µM) before the addition of apoA-I 
and sedimentation of the aggregates formed. The concentrations shown represent the amount of 
heparin remaining in solution after removal of the insoluble material.  (E) Fluorescence lifetime image 
(obtained on a Picoquant MicroTime 200 instrument operating at an excitation wavelength of 375 nm) 
of apoA-I fibrils formed with a 2-fold molar excess of heparin doped with 1 % w/w of a heparin-
fluorescein conjugate (ThermoFisher Scientific).  Fibrils were washed with aqueous buffer before 
sedimentation and dispersion onto glass cover slips. The lower image shows the total mean 
fluorescence lifetime corresponding to a best fitting biexponential curve of time constants 1.5 ns and 
4.0 ns. 
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Figure 2. Green tea catechin interactions with apoA-I fibrils. (A) Reverse-phase HPLC analysis of 
a standard aqueous solution of eight green tea catechins: (1) gallocatechin, (2) caffeine, (3) catechin, 
(4) epicatechin, (5) epigallocatechin-3-gallate (EGCG), (6) gallocatechin-3-gallate, (7) epicatechin-3-
gallate, and (8) catechin-3-gallate. (B) HPLC chromatograms of microwave-extracted green tea 
solution (black) and the solution after the addition and removal by sedimentation of apoA-I fibrils 
(red). Arrows highlight the peak height reductions for compounds 5 and 7. (C) Chromatograms of 
green tea solution (black) and the solution after the addition and removal by sedimentation of MAE40 
fibrils (red). The inset shows the chemical structures of EGCG and ECG. (D) Binding of EGCG to 
apoA-I. EGCG was added to protein monomer (36 PM) before incubation (black) or to the preformed 
fibrils (1 mg/mL monomer equivalent; red) as described in Methods. Solid lines represent the best 
fitting Hill plots, yielding the values of Kd and Bmax given in the main text. (E) ThT fluorescence for 
apoA-I incubated in the presence or absence of heparin (2-fold molar excess), and with the addition of 
EGCG or green tea extract, prior to acidification. The arrow denotes the addition of heparin. (F) ThT 
fluorescence for Aȕ40 fibrils incubated with EGCG. All binding curves and ThT plots represent the 
mean of three replicate samples.  
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Figure 3. SSNMR suggests a structural similarity of apoA-I fibrils formed under different 
conditions. (A) 2D 13C-13C solid state NMR spectra (obtained with 20 ms DARR mixing) of 
uniformly 13C-labelled apoA-I aggregates formed at pH 4 in the absence of heparin (left), in the 
presence of heparin (centre) or at pH 6 after oxidation (right)). Key assigned cross-peaks are labelled. 
(B) Horizontal 1D slices through each 2D spectrum at the frequencies of the alanine CĮ-&ȕ cross 
peaks, as denoted by the dashed lines in (A).  Red peaks occur at the expected chemical shift of 
alanine within D-helices and black peaks occur at the expected chHPLFDO VKLIW RI DODQLQH ZLWKLQ ȕ-
strands.  
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Figure 4. Increased protein mobility after treatment of apoA-I fibrils with EGCG. (A) 2D 13C-
13C solid state NMR spectra (obtained with 20 ms DARR mixing) of uniformly 13C-labelled apoA-I 
aggregates. Spectra are shown for fibrils prepared from 36 PM monomer (black) overlaid with spectra 
of pre-formed fibrils after isolation and exposure to 36 PM EGCG (left) or overlaid with spectra of 
fibrils formed from 36 PM monomer in the presence of 36 PM EGCG (right).  (B) Regions of 1D 13C 
INEPT SSNMR spectra of insoluble aggregates (black) and aggregates after exposure to EGCG (red)  
(C) Corresponding regions of a 2D 1H-13C INEPT spectrum of EGCG-treated fibrils (prepared at pH 4 
alone) labelled with assignments for specific amino acids. The blue crosses, linked by red lines to the 
resonances for TE, SE, LE, NE and ME, represent the expected 1H and 13C chemical shifts for those 
amino acids in E-sheet regions. (D) Spectrum of fibrils formed alone from 36 PM apoA-I monomer 
and treated with equimolar EGCG (red) or fibrils formed in the presence of 72 PM heparin and treated 
with 36 PM EGCG (blue). (E) Simulated 2D 1H-13C INEPT spectrum (1HD-13CD region only) based 
on the predicted 1H and 13C chemical shifts of all 243 residues of apoA-I in an D-helical structure. 
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Figure 5. Structure and size of EGCG-remodeled apoA-I fibrils. (A) Far-UV CD spectra of the 
soluble apoA-I remaining in solution after addition of buffer or EGCG followed by removal of 
insoluble fibrils. The colour scheme corresponds to fibrils formed in the absence of heparin and 
incubated with McIlvaine buffer (green) or with EGCG (blue), and fibrils formed in the presence of 
heparin incubated with buffer only (black) or with EGCG (red). (B) Comparison of the CD spectrum 
of EGCG-treated fibrils in the presence of heparin with the spectrum of soluble native apoA-I at pH 7 
(black). The dotted lines indicate the best fits to the spectra obtained with the CONTINLL algorithm. 
(C) Analysis using the Bradford reagent indicates that the soluble protein released from fibrils formed 
in the presence of heparin increases with increasing EGCG concentration up to a 5-fold molar excess 
over apoA-I.  (D) DLS of the supernatant following centrifugation and removal of buffer-treated 
apoA-I aggregates and apoA-I aggregates treated with EGCG.  
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Figure 6.  Morphology of EGCG-remodeled apoA-I fibrils (A) Negative stain TEM images of 
EGCG the insoluble (pellet) and soluble (supernatant) fractions of apoA-I aggregates formed alone or 
after exposure to EGCG. (B) TEM images of the insoluble and soluble fractions of apoA-I aggregates 
formed in the presence of heparin before exposure to EGCG. (C) TEM images of MAE40 fibrils in 
the absence or presence of EGCG. In each case, fibrils were formed from 36 PM protein monomer 
alone or in the presence of 72 PM heparin, to which was added buffer or EGCG to a final 
concentration of 36 PM.  All scale bars = 500 nm unless indicated otherwise.   
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Figure 7.  Effect of EGCG-treated apoA-I fibrils on the viability of human umbilical artery 
endothelial cells. (A) Effect on cell viability of apoA-I fibrils after exposure to different 
concentrations of EGCG.  (B) Effect on cell viability of apoA-1 fibrils formed in the presence of 
heparin after different concentrations of EGCG.  (C) Control measurements of cell viability after the 
addition of heparin, EGCG or a mixture of both. Means and standard errors are shown for n = 5 for 
each sample group except for the control cells only, for which n = 15. (D) Release of heparin from 
apoA-I fibrils into aqueous solution by the addition of different concentrations of EGCG. Fibrils were 
formed from 36 PM apoA-I in the presence of 72 PM heparin doped with 1 % w/w fluorescein-
heparin conjugate, which was detected by absorbance at 495 nm. 
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Figure 8. EGCG interactions with apoA-I and heparin.  (A) Concentration-dependent effect of 
EGCG in solubilising heparin from apoA-I fibrils.  Fibrils were formed with a 2-fold molar excess of 
heparin, of which 10 % was the fluorescein conjugate. The absorbance of fluorescein at 496 nm was 
measured from the supernatant after removal of the insoluble fibrils by centrifugation. (B) 
Concentration-dependent effect of EGCG in solubilising protein from apoA-I fibrils, measured using 
the Bradford assay. 1D 1H NMR spectrum (black) and waterLOGSY spectrum (red) of EGCG (720 
PM) either (C) alone, (D) in the presence of apoA-I (36 PM), or (E) in the presence of heparin (36 
PM).  
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Figure 9. EGCG interacts with apoA-I in the unmodified polyphenol form. (A) LCMS 
chromatogram of a solution of EGCG incubated with apoA-I for 3 days (after removal of insoluble 
material), containing positive mode XIC 459.0922 m/z (black), and negative mode XIC 457.0776 m/z 
(red). (B) Peak areas measured from chromatograms (positive and negative mode XIC) after 
incubation of EGCG and apoA-I +/- heparin for 0, 1, 2 and 3 days. (C) An example of ESI+ HRMS 
mass assignment of EGCG at tR = 7.65 min; 459.0903 m/z measured, 459.0922 m/z predicted for the 
C22H18O11 [M+H]+ ion. (D) Proton-decoupled 15N CP-MAS NMR spectra of uniformly-15N-labeled 
apoA-I fibrils (prepared at pH 4 in the absence of heparin) before (top) and after (bottom) incubation 
with EGCG for 24 h.  
 
 
